Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) refers to the expansion of cells of hematopoietic lineage that carry acquired somatic alterations associated with hematologic malignancies. The most commonly altered genes giving rise to CHIP are DNMT3A, TET2, and ASXL1. However, advanced sequencing technologies have resulted in highly sensitive detection of clonal hematopoiesis beyond these known driver genes. In practice, CHIP is commonly identified as an incidental finding in liquid and tissue biopsies of patients with solid tumors. CHIP can have broad clinical consequences, given its association with hematologic malignancies and nonmalignant diseases. CHIP can also interfere with next-generation DNA sequencing results, so clinicians should pay careful attention when these results are being used to guide therapy. Future research is needed to determine how solid tumor malignancies and their treatments alter the progression of CHIP, and in turn, how CHIP might be used to improve treatment selection and outcomes for patients with solid tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4107-4113 |
| Number of pages | 7 |
| Journal | Cancer Research |
| Volume | 82 |
| Issue number | 22 |
| DOIs | |
| State | Published - Nov 15 2022 |
Bibliographical note
Funding Information:C.H. Marshall reports grants from V Foundation and Prostate Cancer Foundation during the conduct of the study and personal fees from Dendreon, Bayer, McGraw Hill, Obseva, Astellas, and MashupMD outside the submitted work. E.S. Antonarakis reports grants from Janssen, Johnson & Johnson, Sanofi, Bristol Myers Squibb, Pfizer, AstraZeneca, Novartis, Curium, Constellation, ESSA, Celgene, Merck, Bayer, Clovis; personal fees from Janssen, Astellas, Sanofi, Dendreon, Bayer, Bristol Myers Squibb, Amgen, ESSA, Constellation, Blue Earth, Exact Sciences, Invitae, Curium, Pfizer, Merck, AstraZeneca, Clovis, Eli Lilly; and is a co-inventor of a patented AR-V7 technology that has been licensed to Qiagen. No disclosures were reported by the other authors.
Funding Information:
This work is partially supported by the National Institutes of Health Cancer Center Support Grants P30 CA006973, V Foundation, and the Prostate Cancer Foundation.
Publisher Copyright:
© 2022 American Association for Cancer Research.
